ExpreS2ion Biotech (Sweden) Performance
| EXPRS2 Stock | SEK 27.30 0.30 1.11% |
On a scale of 0 to 100, ExpreS2ion Biotech holds a performance score of 8. The firm shows a Beta (market volatility) of -2.49, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ExpreS2ion Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, ExpreS2ion Biotech is expected to outperform it. Please check ExpreS2ion Biotech's value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether ExpreS2ion Biotech's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ExpreS2ion Biotech Holding are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, ExpreS2ion Biotech sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 106.8 M | |
| Total Cashflows From Investing Activities | -100.9 M |
ExpreS2ion |
ExpreS2ion Biotech Relative Risk vs. Return Landscape
If you would invest 1,976 in ExpreS2ion Biotech Holding on April 28, 2025 and sell it today you would earn a total of 754.00 from holding ExpreS2ion Biotech Holding or generate 38.16% return on investment over 90 days. ExpreS2ion Biotech Holding is generating 0.7289% of daily returns and assumes 6.86% volatility on return distribution over the 90 days horizon. Simply put, 61% of stocks are less volatile than ExpreS2ion, and 86% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ExpreS2ion Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ExpreS2ion Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ExpreS2ion Biotech Holding, and traders can use it to determine the average amount a ExpreS2ion Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1062
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EXPRS2 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.86 actual daily | 61 61% of assets are less volatile |
Expected Return
| 0.73 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average ExpreS2ion Biotech is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ExpreS2ion Biotech by adding it to a well-diversified portfolio.
ExpreS2ion Biotech Fundamentals Growth
ExpreS2ion Stock prices reflect investors' perceptions of the future prospects and financial health of ExpreS2ion Biotech, and ExpreS2ion Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ExpreS2ion Stock performance.
| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 | |||
| Operating Margin | (20.75) % | |||
| Current Valuation | 361.15 M | |||
| Shares Outstanding | 37.15 M | |||
| Price To Book | 3.42 X | |||
| Price To Sales | 55.94 X | |||
| Revenue | 12.23 M | |||
| EBITDA | (45.5 M) | |||
| Cash And Equivalents | 10.14 M | |||
| Cash Per Share | 0.75 X | |||
| Total Debt | 3.48 M | |||
| Debt To Equity | 10.40 % | |||
| Book Value Per Share | 2.75 X | |||
| Cash Flow From Operations | (45.65 M) | |||
| Earnings Per Share | (1.55) X | |||
| Total Asset | 151.96 M | |||
About ExpreS2ion Biotech Performance
By analyzing ExpreS2ion Biotech's fundamental ratios, stakeholders can gain valuable insights into ExpreS2ion Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ExpreS2ion Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ExpreS2ion Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ExpreS2ion Biotech Holding AB , through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. ExpreS2ion Biotech Holding AB is based in Horsholm, Denmark. ExpreS2ion Biotech operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 15 people.Things to note about ExpreS2ion Biotech performance evaluation
Checking the ongoing alerts about ExpreS2ion Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ExpreS2ion Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ExpreS2ion Biotech is way too risky over 90 days horizon | |
| ExpreS2ion Biotech appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 12.23 M. Net Loss for the year was (43.92 M) with profit before overhead, payroll, taxes, and interest of 1.07 M. | |
| ExpreS2ion Biotech Holding has accumulated about 10.14 M in cash with (45.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. |
- Analyzing ExpreS2ion Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ExpreS2ion Biotech's stock is overvalued or undervalued compared to its peers.
- Examining ExpreS2ion Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ExpreS2ion Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ExpreS2ion Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ExpreS2ion Biotech's stock. These opinions can provide insight into ExpreS2ion Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ExpreS2ion Stock analysis
When running ExpreS2ion Biotech's price analysis, check to measure ExpreS2ion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ExpreS2ion Biotech is operating at the current time. Most of ExpreS2ion Biotech's value examination focuses on studying past and present price action to predict the probability of ExpreS2ion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ExpreS2ion Biotech's price. Additionally, you may evaluate how the addition of ExpreS2ion Biotech to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |